^
    BIOMARKER:

    PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule




    Show legend

    Include preclinical:
    Non Small Cell Lung Cancer
    Squamous Cell Carcinoma of Head and Neck
    Gastric Cancer
    Urothelial Cancer
    Triple Negative Breast Cancer
    Renal Cell Carcinoma
    Gastroesophageal Junction Adenocarcinoma
    Cervical Cancer
    Melanoma
    Lung Non-Small Cell Squamous Cancer
    Esophageal Squamous Cell Carcinoma
    Biliary Tract Cancer
    Lung Non-Squamous Non-Small Cell Cancer
    Nasopharyngeal Carcinoma
    Hepatocellular Cancer
    Bladder Cancer
    Lung Adenocarcinoma
    Small Cell Lung Cancer
    Gastric Adenocarcinoma
    Gastroesophageal Cancer
    Ovarian Cancer
    Head and Neck Cancer
    Prostate Cancer
    Colorectal Cancer
    Solid Tumor
    Breast Cancer
    Soft Tissue Sarcoma
    Neuroendocrine Tumor
    HER2 Positive Breast Cancer
    Esophageal Adenocarcinoma
    Diffuse Large B Cell Lymphoma
    Clear Cell Renal Cell Carcinoma
    Pancreatic Ductal Adenocarcinoma
    Anal Carcinoma
    Cholangiocarcinoma
    Salivary Gland Cancer
    Endometrial Cancer
    Esophageal Cancer
    Gallbladder Cancer
    Rhabdomyosarcoma
    Squamous Cell Skin Cancer
    HER2 Negative Breast Cancer
    Vulvar Cancer
    Rectal Cancer
    Kidney Cancer
    Sarcoma
    Gastrointestinal Stromal Tumor
    Thymic Carcinoma
    Lymphoma
    Oropharyngeal Cancer
    Kaposi Sarcoma
    Oral Cancer
    Pancreatic Cancer
    Glioblastoma
    Penile Cancer
    Cutaneous Melanoma
    Peritoneal Cancer
    Merkel Cell Carcinoma
    Thyroid Gland Carcinoma
    Osteosarcoma
    Fallopian Tube Cancer
    Non-Hodgkin’s Lymphoma
    Malignant Pleural Mesothelioma
    Basal Cell Carcinoma
    Hodgkin Lymphoma
    Mucosal Melanoma
    Colon Cancer
    Lung Cancer
    pembrolizumab
    PD1 inhibitor
    Immunotherapy
    nivolumab
    PD-L1-targeted CAR-T immunotherapy
    R-CHOP
    VEGF inhibitor
    PD-L1 inhibitor
    T-lymphocyte cell therapy
    PD1 inhibitor + Angiogenesis inhibitor
    Immunotherapy + Angiogenesis inhibitor
    CPB
    durvalumab + tremelimumab
    nivolumab + ipilimumab
    toripalimab-tpzi
    tislelizumab
    atezolizumab
    cetuximab
    methotrexate
    5-fluorouracil
    durvalumab
    avelumab
    sintilimab
    pembrolizumab + axitinib
    pembrolizumab + lenvatinib
    zimberelimab
    sugemalimab
    camrelizumab
    penpulimab
    sintilimab + fruquintinib
    cemiplimab-rwlc
    toripalimab-tpzi + surufatinib
    pembrolizumab + eftilagimod alpha
    cadonilimab
    bevacizumab + atezolizumab
    camrelizumab + rivoceranib
    pembrolizumab + ramucirumab
    KN046
    avelumab + axitinib
    nivolumab + cabozantinib tablet
    tislelizumab + BGB-A1217
    nivolumab + bevacizumab
    serplulimab
    atezolizumab + RG6058
    bevacizumab
    lenvatinib + toripalimab-tpzi
    pembrolizumab + margetuximab
    lenvatinib
    pembrolizumab + ado-trastuzumab emtansine
    pucotenlimab
    pembrolizumab + INCB024360
    ABBV-181
    pembrolizumab + tirvalimogene teraplasmid
    pembrolizumab + NLG8189
    pembrolizumab + trametinib
    pembrolizumab + niraparib
    pembrolizumab + cetuximab
    pembrolizumab + trastuzumab
    nivolumab + CTL-002
    pembrolizumab + binimetinib
    gemcitabine
    trilaciclib
    durvalumab + TEW-7197
    PM1003
    MT-6402
    nivolumab + HS-110
    sunitinib
    pembrolizumab + eribulin mesylate
    toripalimab-tpzi + rivoceranib
    sintilimab + chidamide
    RRx-001
    atezolizumab + ado-trastuzumab emtansine
    nivolumab + BMS-986205
    pembrolizumab + GSK3359609
    olaparib + durvalumab + cediranib
    anlotinib + sintilimab
    AGEN2034 + UGN-301
    PAS
    trabectedin
    camrelizumab + SHR 1020
    ABSK091
    durvalumab + ABSK091
    durvalumab + AZD2014
    regorafenib
    durvalumab + AZD6738
    dostarlimab-gxly
    sintilimab + lenvatinib
    pembrolizumab + MK-7684
    pembrolizumab + SNK01
    nivolumab + DV281
    nivolumab + ramucirumab
    pembrolizumab + MK-1308
    carboplatin + camrelizumab + pemetrexed
    SV-BR-1-GM
    ipilimumab + cemiplimab-rwlc
    PDR001
    STI-A1014
    BNT327
    pembrolizumab + MK-4280
    paclitaxel + minnelide
    AGEN2034 + AGEN1181
    AZD2936
    pembrolizumab + enfortumab vedotin-ejfv
    anlotinib + penpulimab
    envafolimab
    pembrolizumab + bevacizumab
    tislelizumab + MGCD516
    pembrolizumab + MVP-S
    pembrolizumab + BCA101
    IMU-201
    toripalimab-tpzi + axitinib
    tislelizumab + DKN-01
    pembrolizumab + DS-1062a
    serplulimab + HLX07
    trastuzumab
    geptanolimab
    PF-08046054
    atezolizumab + GS-4721
    atezolizumab + tocilizumab
    aglatimagene besadenovec
    sorafenib + tislelizumab
    pembrolizumab + HB-200
    AGEN2034
    pembrolizumab + IO102-IO103
    retifanlimab-dlwr
    M7824
    cemiplimab-rwlc + isatuximab-irfc
    cetuximab + toripalimab-tpzi
    toripalimab-tpzi + disitamab vedotin
    SNG-162
    bevacizumab + atezolizumab + IPI-549
    bevacizumab + albumin-bound paclitaxel + IPI-549
    pazopanib
    chlorambucil
    avelumab + CYNK-101
    eribulin mesylate
    crizotinib
    CCX559
    SAR445710
    Opal